4
Changes in Ownership
Enliven Therapeutics, Inc. Filed Acc 0001415889-24-010232
Director sold 3,237 shares at $19.08 ($61,758)
- Director acquired 3,237 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Ballal Rahul D. Director | 2024-04-01 | Option exercise 10b5-1 | +94 | $12.60 | $1,184 | 22,435 | D |
| Ballal Rahul D. Director | 2024-04-01 | Option exercise 10b5-1 | +3,143 | $5.52 | $17,349 | 25,578 | D |
| Ballal Rahul D. Director | 2024-04-01 | Sale 10b5-1 | −3,237 | $19.08 | $61,758 | 22,341 | D |
| Derivatives | |||||||
| Ballal Rahul D. Director | 2024-04-01 | Option exercise · Stock Option (right to buy) 10b5-1 | −94 | 65,905 | D | ||
| Ballal Rahul D. Director | 2024-04-01 | Option exercise · Stock Option (right to buy) 10b5-1 | −3,143 | 16,428 | D | ||
| Open-market sales · 3,237 sh · avg $19.08 · $61,758 | |||||||
Loading xslF345X05/form4-04042024_010458.xml…